Glatiramer Acetate

醋酸格拉替雷

Report date: 2026/04/24 20:01:59
NME

Base Information

Drug NameGlatiramer Acetate
Drug Alias Name醋酸格列默Copolymer-1醋酸格拉太咪尔醋酸格拉替雷醋酸格拉替美 +[14] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsAcutely decompensated congestive heart failureCytokine Release SyndromeInflammation +[12] 
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaMultiple Sclerosis
Original Approved Country/TerritoryUnited States
Original Approved Date1996/12/20
Country/TerritoryCzechiaBelgiumBosnia and Herzegovina +[33] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesWeizmann Institute Of ScienceProneuron Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesMapi Pharma LtdWeizmann Institute Of ScienceTeva Pharmaceuticals Ltd +[6] 
Inactive CompaniesSynthon BvTeva Neuroscience IncTeva Branded Pharmaceutical Products R&D Inc +[7] 
Active IndicationsAcutely decompensated congestive heart failureCytokine Release SyndromeInflammation +[8] 
Inactive IndicationsGlaucoma, Angle-ClosureOptic NeuritisAmyotrophic Lateral Sclerosis +[4] 

Other Information

ATC CodeL03AX13
Related LinksWikipediaDrugBankKEGG